Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination

Main Article Content

Stefanie Altmann
Orange Park Medical Center, Department of Dermatology

Dominique Jacobs
Philadelphia College of Osteopathic Medicine

Thomas Brown
Orange Park Medical Center, Department of Dermatology

Preetha Kamath
Orange Park Medical Center

Karthik Krishnamurthy
Orange Park Medical Center

Keywords

Pemphigoid, Bullous Pemphigoid, BP, COVID-19 vaccine adverse effects, SARS-CoV-2, COVID-19, Moderna COVID-19 mRNA vaccine, autoimmune bullous disease, anti-laminin gamma-1 (p200) pemphigoid, p200 pemphigoid

Abstract

As the SARS-CoV-2 vaccinated population increases, there have been many reports of vaccine-induced cutaneous reactions but scarce information on vaccine-induced autoimmune bullous disease. Vaccinations have been associated with the unmasking or development of autoimmune bullous disease; however, there is little data on SARS-CoV-2, specifically. We report a rare case of new-onset pemphigoid in a 70-year-old male following the second dose of the mRNA-1273 vaccine. The patient’s disease has been refractory to treatment, thus the underlying pathophysiology in vaccine-induced pemphigoid is likely unique, and further investigation into this pathophysiology is warranted.

References

1. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after moderna and pfizer COVID-19 vaccination: A registry-based study of 414 cases. Journal of the American Academy of Dermatology. 2021;85(1):46-55. https://dx.doi.org/10.1016/j.jaad.2021.03.092. doi: 10.1016/j.jaad.2021.03.092.

2. Kasperkiewicz M, Woodley DT. Association between vaccination and autoimmune bullous diseases: A systematic review. J Am Acad Dermatol. 2021. Accessed Aug 20, 2021. doi: 10.1016/j.jaad.2021.04.061.

3. Tomayko MM, Damsky W, Fathy R, et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol. 2021. doi: S0091-6749(21)01054-X [pii].

4. Vadalà M, Poddighe D, Laurino C, Palmieri B. Vaccination and autoimmune diseases: Is prevention of adverse health effects on the horizon? EPMA J. 2017;8(3):295-311. Accessed Aug 21, 2021. doi: 10.1007/s13167-017-0101-y.

5. Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: Overview and potential explanations. Front Med (Lausanne). 2018;5:220. Accessed Aug 21, 2021. doi: 10.3389/fmed.2018.00220.

6. Kong J, Cuevas-Castillo F, Nassar M, et al. Bullous drug eruption after second dose of mRNA-1273 (moderna) COVID-19 vaccine: Case report. J Infect Public Health. 2021. Accessed Aug 12, 2021. doi: 10.1016/j.jiph.2021.06.021.

7. Kim A, Khan M, Lin A, Wang H, Siegel L, Rozenberg S. New bullous eruptions in a COVID-19 positive patient in an intensive care unit. J of Skin. 2021;5(3):278-282. https://jofskin.org. Accessed Aug 12, 2021. doi: 10.25251/skin.5.3.9.

8. Olson N, Eckhardt D, Delano A. New-onset bullous pemphigoid in a COVID-19 patient. Case Rep Dermatol Med. 2021;2021:5575111. doi: 10.1155/2021/5575111 [doi].

9. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nature reviews. Drug discovery. 2018;17(4):261-279. https://www.ncbi.nlm.nih.gov/pubmed/29326426. doi: 10.1038/nrd.2017.243.

Article Sidebar

PDF
Published
May 6, 2022
DOI https://doi.org/10.25251/skin.6.3.10

Article Details

How to Cite
Altmann , S., Jacobs, D. ., Brown, T. ., Kamath, P. ., & Krishnamurthy, K. . (2022). Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination . SKIN The Journal of Cutaneous Medicine, 6(3), 238–242. https://doi.org/10.25251/skin.6.3.10
Issue
Vol. 6 No. 3 (2022)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.